0000899243-21-006715.txt : 20210216
0000899243-21-006715.hdr.sgml : 20210216
20210216174852
ACCESSION NUMBER: 0000899243-21-006715
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210211
FILED AS OF DATE: 20210216
DATE AS OF CHANGE: 20210216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAVIS JOHN C. JR
CENTRAL INDEX KEY: 0001741287
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38541
FILM NUMBER: 21641392
MAIL ADDRESS:
STREET 1: C/O MAGENTA THERAPEUTICS
STREET 2: 50 HAMPSHIRE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Magenta Therapeutics, Inc.
CENTRAL INDEX KEY: 0001690585
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-201-2700
MAIL ADDRESS:
STREET 1: 100 TECHNOLOGY SQUARE
STREET 2: 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-11
0
0001690585
Magenta Therapeutics, Inc.
MGTA
0001741287
DAVIS JOHN C. JR
C/O MAGENTA THERAPEUTICS, INC.
100 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Stock Option (Right to Buy)
10.80
2021-02-11
4
A
0
72500
0.00
A
2031-02-10
Common Stock
72500
72500
D
This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021.
Title: Head of Research and Development and Chief Medical Officer
/s/ Zoran Zdraveski, Attorney-in-Fact for John C. Davis Jr.
2021-02-16